GRFT-M03 - Medical / Health Care

GRFT-M03 is a unique calcium phosphate composition to be mixed with autologous blood. GRFT-M03 technology is expected to provide an osteogenic performance comparable to those of autologous bone and BMPs (bone remodeling and reconstruction), with an improved safety profile.

The targeted clinical indications are orientated to “salvage” situations (osteonecrosis, non-unions, revision on elderly patients, large bone defect (e.g. acetabular reconstruction), bone anchorage augmentation (high injectability, plasticity), minimally invasive injection in fusion cages for intervertebral body fusion after placement of cage, minimally invasive procedures requiring higher pressure and lower viscosity, such as bone marrow lesions and tibioplasty.

The first CE-mark and FDA clearance are planned for early 2018.